

AMENDMENTS TO THE CLAIMS

13. (Currently amended) A method to elicit an antitumor immune response to prostate tumors in a subject, which method comprises
administering to said subject at least one active ingredient formulated for administration to said subject,
wherein said active ingredient comprises or expresses at least one antigen over-represented in the prostate gland ~~or an immunologically effective portion thereof,~~
wherein said antigen is ~~an immunologically reactive portion of human prostate specific antigen (PSA); or~~
~~human prostate-specific membrane antigen) (PSMA) or an immunologically effective portion thereof; or~~
human prostate-specific membrane antigen (PSMA) ~~or an immunologically effective portion thereof; or~~
prostatic acid phosphatase (PAP) ~~or an immunologically reactive portion thereof; or~~ mixtures of the foregoing; or
wherein said active ingredient comprises said at least one antigen or a nucleic acid that generates said antigen or antigens *in situ*.
15. (Previously amended) The method of claim 13 wherein said active ingredient is human PSMA.
16. (Previously amended) The method of claim 13 wherein said active ingredient is PAP.
18. (Previously amended) The method of claim 13 wherein said active ingredient is a nucleic acid that generates PSMA *in situ*.
19. (Previously amended) The method of claim 13 wherein said active ingredient is a nucleic acid that generates said PAP *in situ*.

20. (Original) The method of claim 13 wherein the active ingredient is encapsulated in liposomes and/or coupled to liposomes.

21. (Original) The method of claim 20 wherein said liposomes contain an adjuvant.

22. (Original) The method of claim 13 which further includes at least one adjuvant that enhances the antitumor immune response.

23. (Original) The method of claim 22 wherein said adjuvant is selected from the group consisting of Freund's complete adjuvant; alum; lipid A; monophosphoryl lipid A; *Bacillus Calmette-Guerin* (BCG) or other bacteria polysaccharides; saponins; detoxified endotoxin (DETOX); muramyl tripeptide or muramyl dipeptide or their derivatives; SAF1; lymphokines; cytokines; colony stimulating factors; nonionic block copolymers; and immune stimulating complexes (ISCOMS).

24. (Original) The method of claim 13 wherein said subject is afflicted with metastatic prostate cancer; and/or wherein said subject has been surgically treated to excise said tumor but is at risk for recurrence.